作者：
Rosanne,Janssens [1]
;
Isabelle,Huys [2]
;
Eline,van Overbeeke [2]
;
Chiara,Whichello [3]
;
Sarah,Harding [4]
;
Jürgen,Kübler [5]
;
Juhaeri,Juhaeri [6]
;
Antonio,Ciaglia [7]
;
Steven,Simoens [2]
;
Hilde,Stevens [8]
;
Meredith,Smith [9]
;
Bennett,Levitan [10]
;
Irina,Cleemput [11]
;
Esther,de Bekker-Grob [3]
;
Jorien,Veldwijk [3]
作者单位：
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Herestraat 49, Box 521, 3000, Leuven, Belgium. rosanne.janssens@kuleuven.be.
[1]
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Herestraat 49, Box 521, 3000, Leuven, Belgium.
[2]
Erasmus School of Health Policy & Management (ESHPM) and Erasmus Choice Modelling Centre (ECMC), Erasmus University Rotterdam, P.O. Box 1738, 3000, DR, Rotterdam, The Netherlands.
[3]
Takeda International, UK Branch, 61 Aldwych, London, WC2B 4AE, UK.
[4]
QSciCon, Europabadstr. 8, 35041, Marburg, Germany.
[5]
Sanofi, 55 Corporate Drive, Bridgewater Township, NJ, 08807, USA.
[6]
International Alliance of Patients' Organizations, 49-51 East Rd, Hoxton, London, N1 6AH, UK.
[7]
Institute for Interdisciplinary Innovation in healthcare (I3h), Université libre de Bruxelles (ULB), Route de Lennik 808, 1070, Brussels, Belgium.
[8]
Amgen, Inc., Thousand Oaks, California, USA.
[9]
Global R&D Epidemiology, Janssen Research & Development, 1125 Trenton-Harbourton Road, PO Box 200, Titusville, NJ, 08560, USA.
[10]
Belgian Health Care Knowledge Centre (KCE), Kruidtuinlaan 55, 1000, Brussels, Belgium.
[11]
DOI
10.1186/s12911-019-0875-z
PMID
31585538
发布时间
2023-10-14
换一批
换一批
